SCYNEXIS Inc (135A F) stock market data APIs
€0.7853
0(0%)
as of April 30, 2026
Try our APIs with
free plan!
SCYNEXIS Inc Financial Data Overview
Price chart is built with
Anychart
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Prev. Close
0.7853
Open
0.7767
High
0.7862
Low
0.7743
52 wk Range
0.4775-0.982
Market Cap
61 965 K
Shares Outstanding
79 443 K
Revenue
20 601 K
EPS
-0.22
Beta
1.121
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SCYNEXIS Inc data using free add-ons & libraries
Get SCYNEXIS Inc Fundamental Data
SCYNEXIS Inc Fundamental data includes:
- Net Revenue: 20 601 K
- EBITDA: -36 537 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-16
- EPS/Forecast: -0.6
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SCYNEXIS Inc News
New
SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
Scynexis JERSEY CITY, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and dru...
Deadly Fungi Are Becoming More Common And We’re Running Out of Ways to Treat Them
As certain fungi such as Candida auris become more widespread throughout the U.S., deaths related to severe fungal infections are rising. WSJ’s Daniela Hernandez explains what you should know. Dangerous fungi are advancing faster than drugs to contain them.
Doctors Desperately Need Drugs to Kill Deadly Fungi. It’s an Uphill Fight.
As certain fungi such as Candida auris become more widespread throughout the U.S., deaths related to severe fungal infections are rising. WSJ’s Daniela Hernandez explains what you should know. Dangerous fungi are advancing faster than drugs to contain them.
SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK
Scynexis JERSEY CITY, N.J., June 21, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and dru...
Get SCYNEXIS Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
